ArticleEndocrine2025
Sex differences in the onset and outcomes of immune checkpoint inhibitor-induced overt thyroid dysfunction: a retrospective study.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immune checkpoint inhibitor-related endocrinopathies: from immune crosstalk to predictive biomarkers and precision management.Frontiers in endocrinology · 2026Review
- Sex-specific reporting patterns and onset timing of immune-related adverse events associated with nivolumab and pembrolizumab: a dual-database pharmacovigilance analysis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis retrospective cohort study aimed to evaluate sex-specific differences in the onset, progression, and outcomes of immune checkpoint inhibitor (ICI)-induced overt thyroid dysfunction in a real-world oncology population.
methodsWe retrospectively screened electronic medical records of 410 patients with cancer, treated with ICIs who developed to thyroid dysfunction (2018–2024). A total of 118 patients with new-onset overt thyroid dysfunction were included. Thyroid dysfunction was classified as thyrotoxicosis and hypothyroidism and analyzed separately. Kaplan–Meier analysis estimated the time to onset, progression from thyrotoxicosis to hypothyroidism, and subsequent recovery or improvement. Group differences were assessed by log-rank tests. Multivariable Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs).
resultsAmong the 118 patients, 53 (44.92%) developed overt thyrotoxicosis and 65 (55.08%), overt hypothyroidism. Median time to onset was 10.00 weeks (interquartile range [IQR]: 6.00–16.75). Thyrotoxicosis onset occurred earlier than hypothyroidism (median: 7.00 weeks; IQR: 5.00–9.00 vs. 14.00 weeks; IQR: 10.00–19.00; P < 0.001). Females experienced earlier thyrotoxicosis onset than males (median: 6.50 vs. 8.00 weeks; adjusted HR: 5.35; 95% CI: 1.10–26.10; P = 0.038). Among patients with overt thyrotoxicosis, 83.02% progressed to hypothyroidism within 7.00 weeks (IQR: 4.75–9.00) with no sex difference. The median recovery time from thyrotoxicosis was 123.50 weeks (IQR: 98.50–145.50), with males showing longer recovery (median 128.00 vs. 105.00 weeks; HR: 0.53; 95% CI: 0.25–1.10; P = 0.042), but it was not significant after adjustment. Among patients with overt hypothyroidism, 88.33% showed improvements within 8.00 weeks (IQR: 5.00–11.00), without a significant sex difference.
conclusionsFemale patients experience earlier onset of ICI-induced overt thyrotoxicosis and faster recovery from hypothyroidism than males. These sex-specific temporal patterns indicate the need for intensified thyroid monitoring every 2–3 weeks during the first 2 months of ICI therapy in female patients.
Indexed as
Identifiers
41075126What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.